Welcome to our dedicated page for Prenetics Global SEC filings (Ticker: PRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Prenetics Global's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Prenetics Global's regulatory disclosures and financial reporting.
Prenetics Global Limited launched a primary offering of 2,722,642 Class A Ordinary Shares at $16.08 per share sold together with one Class A warrant and one Class B warrant, plus warrants to purchase up to 5,445,284 shares and Placement Agent Warrants to purchase up to 131,829 shares. Gross proceeds are $43,779,297.56 with estimated net proceeds of $40.1 million.
Each Class A warrant is exercisable at $24.12 and each Class B warrant at $32.16, both immediately exercisable and expiring five years from issuance; the warrants will not be listed and may have limited liquidity. Dominari Securities LLC acted as exclusive placement agent with fees of 8% (reduced to 4% for certain investors) and warrant coverage. Shares outstanding were 12,524,823 Class A and 1,580,972 Class B prior to the offering and will be 15,247,465 Class A and 1,580,972 Class B immediately after.
The Company intends to use proceeds to expand IM8 globally, develop and implement its Bitcoin treasury strategy, and for working capital and general corporate purposes. The filing highlights risks including immediate dilution, lack of a trading market for the warrants, PFIC considerations, and Bitcoin-related volatility and custody risks.
Prenetics Global Limited furnished a Form 6-K noting it issued a press release announcing the pricing and subscription of its best efforts public offering. The press release is included as Exhibit 99.1. The report is signed by Chief Financial Officer Lo Hoi Chun on October 27, 2025.
Prenetics Global Limited submitted a Form 6-K as a foreign private issuer to provide an update for October 2025. The company states that on October 27, 2025 it issued a press release announcing the pricing of its best efforts public offering. The press release describing this offering is included with the report as Exhibit 99.1.
Prenetics Global Limited launched a preliminary prospectus supplement for a primary offering of Class A Ordinary Shares and/or Pre-funded Warrants, each sold together with one Class A Warrant and one Class B Warrant. The Class A and Class B Warrants are exercisable immediately and will expire five years from issuance. The warrants and Pre-funded Warrants will be issued separately but are not being listed, so liquidity may be limited.
Dominari Securities LLC is engaged as exclusive placement agent on a reasonable best efforts basis, with cash fees of 8% of gross proceeds (reduced to 4% for company-introduced investors) and placement agent warrants equal to up to 6% of the securities sold (reduced to 2% for directed orders). Pre-funded Warrants are available to investors whose share purchases would otherwise exceed 4.99% (or, at the purchaser’s election, 9.99%) beneficial ownership. Net proceeds are intended for IM8 global expansion, development and implementation of the Company’s Bitcoin treasury strategy, working capital and general corporate purposes.
Prenetics Global Limited furnished a Form 6-K noting it issued a press release announcing a proposed public offering. The company states that the press release, dated October 24, 2025, is provided as Exhibit 99.1 to this report.
The filing lists the exhibit and includes the company’s authorization by Chief Financial Officer Lo Hoi Chun.
Prenetics Global Limited furnished Amendment No. 1 to Form 6-K, adding its condensed consolidated financial statements for the six months ended June 30, 2025 as Exhibit 99.2. The amendment supplements the September 12, 2025 Form 6-K that included business updates and unaudited Q2 results and does not change other information. This report is incorporated by reference into the company’s Form F-3 and Form S-8 registration statements.
Prenetics Global Limited filed Amendment No. 2 to its Form 6-K to update the risk disclosure tied to its bitcoin treasury strategy. The amendment replaces and supersedes the prior Exhibit 99.1 in an earlier Form 6-K/A, which itself had replaced the original Form 6-K risk factor exhibit. Other disclosures in the earlier Form 6-K and Form 6-K/A remain unchanged. The filing also reiterates that statements about expectations and future performance are forward-looking and subject to significant risks and uncertainties referenced in the company’s Form 20-F and other SEC filings.
On 1 Aug 2025, Prenetics Global Limited (NASDAQ: PRE) reported the results of an Extraordinary General Meeting via Form 6-K. Shareholders approved two resolutions:
- Proposal 1 – Authorised Share Capital Increase: the authorised capital rises from US$50,000 (33.3 m shares) to US$320,000 (213.3 m shares) at the unchanged par value of US$0.0015. This adds 160 m Class A shares, 12 m Class B convertible shares and 8 m undesignated shares. The motion passed with 4,250,875 votes FOR versus 503,820 AGAINST (≈78.7% support).
- Proposal 2 – Administrative Filing Authority: authorises the company’s registered office provider to file the amended charter with Cayman authorities. Passed with 4,744,054 FOR and only 14,922 AGAINST.
No financial results were disclosed. Approval materially expands the company’s capacity to issue new equity, signalling potential future capital raises and possible dilution for existing holders.